The estimated Net Worth of Thomas Mitchell W is at least $1.99 Миллион dollars as of 23 June 2015. Thomas W owns over 15,000 units of Neurocrine Biosciences stock worth over $1,943,520 and over the last 21 years Thomas sold NBIX stock worth over $48,937.
Thomas has made over 9 trades of the Neurocrine Biosciences stock since 2012, according to the Form 4 filled with the SEC. Most recently Thomas exercised 15,000 units of NBIX stock worth $99,900 on 23 June 2015.
The largest trade Thomas's ever made was exercising 45,000 units of Neurocrine Biosciences stock on 13 January 2015 worth over $202,950. On average, Thomas trades about 3,950 units every 36 days since 2003. As of 23 June 2015 Thomas still owns at least 16,000 units of Neurocrine Biosciences stock.
You can see the complete history of Thomas W stock trades at the bottom of the page.
Thomas's mailing address filed with the SEC is , , , , .
Over the last 22 years, insiders at Neurocrine Biosciences have traded over $159,913,426 worth of Neurocrine Biosciences stock and bought 103,400 units worth $589,660 . The most active insiders traders include Partners L P/Ilbiotechnolog..., Partners L P/Ilbiotechnolog... и Richard F Pops. On average, Neurocrine Biosciences executives and independent directors trade stock every 8 days with the average trade being worth of $1,567,813. The most recent stock trade was executed by William H Rastetter on 15 August 2024, trading 14,250 units of NBIX stock currently worth $2,090,333.
neurocrine biosciences, inc of san diego is a product based biopharmaceutical company focusing on the development and commercialization of innovative pharmaceutical products to treat unmet medical needs. the company's research and development efforts are focused on neurological and endocrine diseases and disorders. our product candidates address some of the largest pharmaceutical markets in the world including endometriosis, irritable bowel syndrome, anxiety, depression, pain, diabetes, insomnia, and other neurological and endocrine related diseases and disorders
Neurocrine Biosciences executives and other stock owners filed with the SEC include: